{"groups":[{"description":"Dose escalation of rebastinib 50 milligram (mg) twice daily (BID) orally (PO) in combination with paclitaxel administered by intravenous (IV) infusion at 80 mg/meter squared (m\\^2) on days 1, 8, and 15 of repeated 28-day cycles.","id":"FG000","title":"Part 1 Arm 1 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose escalation of rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"FG001","title":"Part 1 Arm 2 Rebastinib 100 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in triple-negative breast cancer (TNBC). Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"FG002","title":"Part 2 Cohort 1 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in TNBC. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"FG003","title":"Part 2 Cohort 1 Rebastinib 100 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in inflammatory breast cancer. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"FG004","title":"Part 2 Cohort 2 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in inflammatory breast cancer. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"FG005","title":"Part 2 Cohort 2 Rebastinib 100 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in ovarian cancer. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 repeated 28-day cycles.","id":"FG006","title":"Part 2 Cohort 3 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in ovarian cancer. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"FG007","title":"Part 2 Cohort 3 Rebastinib 100 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in endometrial cancer. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"FG008","title":"Part 2 Cohort 4 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in endometrial cancer. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"FG009","title":"Part 2 Cohort 4 Rebastinib 100 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in gynecological carcinosarcoma (GCS). Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"FG010","title":"Part 2 Cohort 5 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"19"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"15"},{"groupId":"FG005","numSubjects":"5"},{"groupId":"FG006","numSubjects":"28"},{"groupId":"FG007","numSubjects":"10"},{"groupId":"FG008","numSubjects":"22"},{"groupId":"FG009","numSubjects":"16"},{"groupId":"FG010","numSubjects":"20"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"14"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"13"},{"groupId":"FG005","numSubjects":"4"},{"groupId":"FG006","numSubjects":"26"},{"groupId":"FG007","numSubjects":"9"},{"groupId":"FG008","numSubjects":"20"},{"groupId":"FG009","numSubjects":"14"},{"groupId":"FG010","numSubjects":"19"}],"comment":"Modified Intent-to-Treat (mITT) Population includes all participants who had at least one dose of the combined study drugs, had measurable disease at baseline, and had at least one post-baseline assessment. Participants without a post-baseline assessment who discontinued study treatment due to clinical progression, death, or a rebastinib-related AE will also be included in the mITT population.","type":"mITT Population"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"9"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"12"},{"groupId":"FG007","numSubjects":"5"},{"groupId":"FG008","numSubjects":"9"},{"groupId":"FG009","numSubjects":"5"},{"groupId":"FG010","numSubjects":"7"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"7"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"16"},{"groupId":"FG007","numSubjects":"5"},{"groupId":"FG008","numSubjects":"13"},{"groupId":"FG009","numSubjects":"11"},{"groupId":"FG010","numSubjects":"13"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}